---
title: CRO Daily News — July 29, 2026
slug: daily-news-2026-07-29-cro
site: cro
post_kind: news
byline: BioBM
description: July 29 CRO daily: Why Clinical Trials Are Leaving the US: Expert Q&A on FDA's Project TrialBlazer Limits — CRO directors should expect continued Phase 1…
canonical_url: https://www.cro.directory/posts/daily-news-2026-07-29-cro
published_at: 2026-07-29T23:59:23.265Z
last_updated: 2026-07-30T00:00:36.676Z
---

### Why Clinical Trials Are Leaving the US: Expert Q&A on FDA's Project TrialBlazer Limits
- FDA's Project TrialBlazer aims to cut IND review timelines by 6–12 months, but [TruTechnologies](/companies/trutechnologies)' Richard Graham argues the initiative misses systemic bottlenecks driving trials to Australia and China.
- Phase 1 studies are migrating to Australia due to streamlined CTN processes and R&D tax credits; Phase 2–3 trials shift to China, where state-coordinated infrastructure and large treatment-naive patient pools accelerate enrollment and completion.
- Graham identifies fragmented stakeholder alignment—patients, sponsors, sites, CROs, investors, payers, regulators—as the core constraint; single-issue regulatory fixes cannot compete with China's top-down trial coordination model.

**Operational Impact**

CRO directors should expect continued Phase 1 volume loss to Australia and Phase 2–3 shifts to China despite TrialBlazer, signaling that US-based CRO capacity planning must account for structural competitive disadvantages beyond regulatory timelines.

*Source: [Pharmaceutical Executive RSS](https://www.pharmexec.com/view/operation-trialblazer-clinical-trials-leaving-richard-graham)*

## References

1. [Pharmaceutical Executive RSS — Why Clinical Trials Are Leaving the US: Expert Q&A on FDA's Project TrialBlazer Limits](https://www.pharmexec.com/view/operation-trialblazer-clinical-trials-leaving-richard-graham)

Source: https://www.cro.directory/posts/daily-news-2026-07-29-cro